BNR vs CCM
Burning Rock Biotech Ltd. and Concord Medical Services Holdings Ltd., side by side — 8 fiscal years reported in CNY, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BNR | CCM |
|---|---|---|
| Revenue | CNY 539.6M | CNY 460.5M |
| Net income | CNY -55.3M | CNY -92.8M |
| Gross margin | 74.7% | 5.6% |
| Net margin | −10.3% | −82.4% |
| Return on equity | −9.9% | — |
| Diluted EPS | — | −CNY 0.71 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | CNY -33.7M | CNY -258.1M |
| Equity | CNY 535.3M | CNY -2.1B |
| Net debt / equity | −0.89× | — |
| Current ratio | 2.99× | 0.48× |
| Revenue CAGR 5y | 4.6% | 15.6% |
| Profit CAGR 5y | — | — |
BNR bills 1.2× the revenue of CCM, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
8 years side by side
| Fiscal year | BNR | CCM |
|---|---|---|
| FY2025 | CNY 539.6M | CNY 460.5M |
| FY2024 | CNY 515.8M | CNY 384.0M |
| FY2023 | CNY 537.4M | CNY 537.4M |
| FY2022 | CNY 563.2M | CNY 472.1M |
| FY2021 | CNY 507.9M | CNY 485.6M |
| FY2020 | CNY 429.9M | CNY 223.0M |
| FY2019 | CNY 381.7M | CNY 198.4M |
| FY2018 | CNY 208.9M | CNY 190.9M |
Net income by year
Bottom line
| Fiscal year | BNR | CCM |
|---|---|---|
| FY2025 | CNY -55.3M | CNY -92.8M |
| FY2024 | CNY -346.6M | CNY -308.2M |
| FY2023 | CNY -653.7M | CNY -297.7M |
| FY2022 | CNY -971.2M | CNY -489.7M |
| FY2021 | CNY -796.7M | CNY -271.4M |
| FY2020 | CNY -407.2M | CNY -310.0M |
| FY2019 | CNY -169.2M | CNY -307.0M |
| FY2018 | CNY -177.5M | CNY -234.9M |
The companies